Company profile: Osivax
1.1 - Company Overview
Company description
- Provider of immunotherapy vaccines powered by the oligoDOM self-assembling nanoparticle platform to elicit potent T- and B-cell responses and enable universal vaccines against mutating pathogens. Pipeline includes OVX836, a universal influenza A vaccine targeting nucleoprotein; OVX033, a universal sarbecovirus vaccine targeting nucleocapsid; and PANHPVAX, a pan-strain HPV vaccine.
Products and services
- OligoDOM® technology platform: Custom-engineered self-assembling nanoparticle platform that expedites dendritic cell uptake, amplifies natural protein immunogenicity, and triggers potent B-cell responses plus unprecedented CD8 T-cell activation for universal vaccines against mutating pathogens
- OVX033: Broad-spectrum universal sarbecovirus vaccine candidate targeting the nucleocapsid, architected to generate potent T-cell and strong B-cell responses with unprecedented CD8 T-cell activation to protect against current and future sarbecoviruses
- OVX836: Antigen-targeted universal influenza A vaccine candidate leveraging oligoDOM® to focus on nucleoprotein, eliciting strong B-cell and potent T-cell responses, including robust CD8 activation, for broad cross-strain protection
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Osivax
Cidara Therapeutics
HQ: United States
Website
- Description: Provider of drug-Fc conjugate therapeutics built on the Cloudbreak platform, which couples targeted small molecules and peptides to a human antibody fragment (Fc) to inhibit disease targets and engage the immune system; includes CD388, a Phase 2 DFC for preventing seasonal influenza A and B, and CBO421, an IND-enabling oncology DFC targeting CD73 to enhance anti-tumor immunity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cidara Therapeutics company profile →
Tmunity Therapeutics
HQ: United States
Website
- Description: Provider of engineered T cell therapies and platforms, developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms to unleash the immunological potential of T cells, treat a wide range of disease indications, and enable control over T cell activation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tmunity Therapeutics company profile →
Ab Initio Biotherapeutics
HQ: United States
Website
- Description: Provider of antigen discovery and antibody generation solutions using a proprietary platform targeting multi-transmembrane proteins such as GPCRs, supporting therapeutics for neurological, cardiovascular, endocrine and gastrointestinal disorders; offerings include antibody optimization, single B-cell screening of immune repertoires, the OmniAb Discovery Platform, OmniRat and OmniMouse with high-throughput screening.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ab Initio Biotherapeutics company profile →
Vivace Therapeutics
HQ: United States
Website
- Description: Provider of small-molecule YAP-TEAD transcription activity inhibitors targeting the Hippo-YAP pathway for cancer treatment, with a focus on Hippo-YAP pathway research to discover and develop cancer therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vivace Therapeutics company profile →
Nouscom
HQ: Switzerland
Website
- Description: Provider of an immunotherapy platform for cancer, creating modified viral vector vaccines with engineered vectors optimized to express long strings of tumor neoantigens; products: NOUS-209 (off-the-shelf for mismatch repair deficiency and microsatellite instability), NOUS-PEV (personalized vaccine encoding up to 60 neoantigens via VENUS), NOUS-THV-001 (oncolytic Herpes Virus expressing immunomodulatory molecules).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nouscom company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Osivax
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Osivax
2.2 - Growth funds investing in similar companies to Osivax
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Osivax
4.2 - Public trading comparable groups for Osivax
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →